Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation IGF-1 generation test with NutropinAq to predict 1-year growth response in idiopathic short stature
NL-OMON36350Phase 4Withdrawn
- Sponsor
- Ipsen
- Start
- Jul 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of somatropin in Idiopathic Short Stature (ISS), sponsored by Ipsen. Primary endpoints: Primary predictive endpoint, Primary regression analysis and 1 more. Planned start Jul 2011; status: withdrawn.
02
Drugs
somatropin
03
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on NL-OMON36350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36350.